Latest news

  • 21 September 2023
    BTG Pharmaceuticals, a SERB company, to present data on ricin antidote development programme at the North American Congress of Clinical Toxicology
    SERB will present in vivo data for a polyclonal antibody in development as an antidote for ricin poisoning, on the first day of the upcoming NACCT in Montreal.
  • 13 July 2023
    SERB Pharmaceuticals acquires Vistogard® and Xuriden® from Wellstat Therapeutics
    West Conshohocken, PA, 13 July 2023: SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard® (uridine triacetate) and Xuriden® (uridine triacetate), from Wellstat Therapeutics. Both medicines are commercially available in the US and currently distributed across Europe on a named patient or compassionate use basis.  Jeremie Urbain, […]
  • 22 June 2023
    BTG Pharmaceuticals Statement on NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Use of Glucarpidase (Voraxaze®) and
    West Conshohocken, PA, 22 June 2023:  BTG Pharmaceuticals, a SERB company, highlights the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Acute Lymphoblastic Leukemia, B-Cell Lymphomas, Pediatric Acute Lymphoblastic Leukemia, and Pediatric Aggressive Mature B-Cell Lymphomas. i-iv The updated guidelines: “The updated guidelines will help ensure that healthcare professionals understand the current […]

News archive



    You are leaving the global corporate website
    This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
    Choose your region